Literature DB >> 7890578

Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae.

A P Théon1, J R Pascoe, D M Meagher.   

Abstract

Twenty-seven horses (and 1 mule) with 32 histologically confirmed cutaneous tumors were studied to evaluate the effects of intratumoral injection of cisplatin initiated at the time of surgery. As a result of surgery, 9 of the wounds were closed primarily (5 sarcoids, 4 carcinomas) and 23 were left open to granulate (16 sarcoids, 6 carcinomas, 1 hamartoma). Chemotherapy consisted of 4 treatment sessions of intratumoral injection of cisplatin in purified sesame oil at 2-week intervals. The first treatment session was administered intraoperatively. A controlled-release formulation of cisplatin in sesame oil was used to limit drug egress from the injection site. Dosage was 1 mg of cisplatin/cm3 of tissue. The mean relapse-free interval was 41 +/- 3.7 months. The estimates of overall relapse-free survival rates were 92 +/- 5% at 1 year and 77 +/- 11% at 4 years. Cisplatin-related local toxicosis was minimal and wound healing was not compromised. Intratumoral injection of cisplatin appears safe and effective when administered in the perioperative period for selected tumors in equidae.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7890578

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  2 in total

1.  Electrochemotherapy increases local control after incomplete excision of a recurring penile fibrosarcoma in a stallion.

Authors:  E P Spugnini; C Bolaffio; L Scacco; A Baldi
Journal:  Open Vet J       Date:  2016-11-26

2.  Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53.

Authors:  Margaret Finlay; Zhengqiang Yuan; Iain M Morgan; M Saveria Campo; Lubna Nasir
Journal:  Vet Res       Date:  2012-12-04       Impact factor: 3.683

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.